Title
Category
Credits
Event date
Cost
Chronic Myeloid Leukemia: How to Treat During Pregnancy
  • Systemic Light Chain Amyloidosis
  • 0.25 AAPA Category 1 CME credit
  • 0.25 ACPE contact hours
  • 0.25 AMA PRA Category 1 Credit™
  • 0.25 ANCC contact hours
  • 0.25 Participation
$0.00
Chronic myeloid leukemia (CML) can affect individuals of reproductive age, and tyrosine kinase inhibitor (TKI) therapy is known to have teratogenic effects. Discontinuing TKI therapy during pregnancy poses a risk of recurrence. Shared decision making is recommended in the management of patients with CML during pregnancy. Options for fertility preservation and alternatives to TKI therapy should be discussed with all patients.
The Role of JAK Inhibitors in the Management of Myelofibrosis
  • Myeloproliferative Neoplasms
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
$0.00
Allogeneic hematopoietic cell transplant is the only potentially curative treatment option resulting in long-term remissions for patients with myelofibrosis (MF), but it is associated with a significant rate of transplant-related complications and morbidity in patients with lower-risk MF. Patients have a significant symptom burden and a propensity for disease transformation to accelerated and blast phases. For many years, ruxolitinib was the only FDA-approved drug for the treatment of intermediate-risk or high-risk MF. Since then, multiple new JAK inhibitors have been approved by the FDA.
Amyloidosis: Diagnosis, Treatment, and Supportive Care
  • Systemic Light Chain Amyloidosis
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
$0.00
High rates of early mortality in newly diagnosed systemic light-chain amyloidosis (SLCA) suggest that there continues to be a delay in early diagnosis. The initial evaluation must confirm the diagnosis, establish the extent and sites of disease, and evaluate for comorbidities that are likely to have an impact on prognosis and treatment options. Many of the novel agents used in the treatment of multiple myeloma are being utilized in the treatment of SLCA, and the treatment armamentarium is growing.
Archived NCCN Tumor Boards: Multidisciplinary Management of Head and Neck Cancers
  • Head and Neck Cancers
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
$0.00
Despite advances in radiation therapy (RT) techniques for the treatment of head and neck cancers, patients with head and neck cancers continue to be at risk of oral and dental complications after surgery or RT because of treatment-induced xerostomia and salivary gland dysfunction, which are associated with increased dental caries.
Archived NCCN Tumor Boards: New Approaches to Treatment of Bladder Cancer
  • Bladder Cancer
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
$0.00
This activity will help clinicians identify the best treatment options for their patients with bladder cancer.
Recorded Presentation from the NCCN Pharmacy Updates: Maintenance Strategies in the Management of Acute Myeloid Leukemia
  • Acute Myelogenous Leukemia
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Maintenance therapy is an aspect of acute myeloid leukemia (AML) management that currently demonstrates strong promise in efforts to prolong survivability and improve overall survival. Given the forthcoming evidence in this area, it is highly important for health care professionals responsible for the care of patients with AML to be aware of both new treatment standards and emerging research in maintenance therapy options.
CAR T-Cell Therapies in Hematologic Malignancies: Challenges and Strategies
  • Acute Lymphoblastic Leukemia
  • Hematologic Malignancies
  • Multiple Myeloma
  • Non-Hodgkin's Lymphoma
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Multiple CAR T-cell therapies are approved for the treatment of certain relapsed or refractory hematologic malignancies with promising clinical outcomes. However, treatment with CAR T-cell therapy is not without risk and can result in severe and potentially fatal toxicities. Although these toxicities are generally reversible, early recognition and implementation of an appropriate management strategy are essential.
Optimizing the Use of Bispecific Antibodies in Hematologic Malignancies
  • Acute Lymphoblastic Leukemia
  • Hematologic Malignancies
  • Multiple Myeloma
  • Non-Hodgkin's Lymphoma
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Immunotherapy using antibody drug conjugates, immune check point inhibitors, and chimeric antigen receptor (CAR) T-cells has significantly transformed the treatment landscape of relapsed or refractory hematologic malignancies. Bispecific antibodies represent a novel immunotherapy approach with remarkable efficacy for the treatment of relapsed/refractory hematologic malignancies. However, they also have a distinct toxicity profile associated with T-cell activation.
Managing Earlier Integration of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia
  • Acute Lymphoblastic Leukemia
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
$0.00
While blinatumomab has been utilized in the setting of relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) for years, emerging data has shown promising clinical efficacy with its use as post-remission therapy. Knowledge of key trial findings regarding blinatumomab consolidation for both Philadelphia chromosome-positive and Philadelphia chromosome-negative B-ALL may allow providers to choose up-front regimens with the ability to improve rates of molecular response and overall survival.
Review of Oral Targeted Therapies in Acute Myeloid Leukemia
  • Acute Myelogenous Leukemia
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
$0.00
In recent years, there has been an increased emphasis on molecular and genetic alterations in the classification system of acute myeloid leukemia, and, with this, an increase in the development of targeted therapies. Oral targeted therapies such as FLT3 inhibitors and IDH1/2 inhibitors are being increasingly used in the frontline setting. Oral targeted therapies come with unique and potentially life-threatening toxicities, such as cardiac toxicity with FLT3 inhibitors and differentiation syndrome with IDH1/2 inhibitors.

Pages